Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

1.810 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 1.810
Bid (Size) 1.810 (50)
Ask (Size) 1.950 (15)
Prev. Close 1.810
Today's Range 1.810 - 1.810
52wk Range 1.770 - 11.41
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-73.42%
-73.42%
1 Month
-35.82%
-35.82%
3 Month
-74.54%
-74.54%
6 Month
-64.23%
-64.23%
1 Year
-53.71%
-53.71%

More News

Read More
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
US Stocks Mixed; Inflation Rate Falls More Than Projected
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
Via Benzinga
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Beat Down the Bears
Via InvestorPlace
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.